Regenxbio (RGNX) Free Cash Flow (2014 - 2025)

Regenxbio's Free Cash Flow history runs 12 years deep, the most recent figure standing at -$54.4 million for Q4 2025.

• In Q4 2025, Free Cash Flow fell 73.96% year-over-year to -$54.4 million; the TTM figure through Dec 2025 stood at -$126.4 million (up 26.66% YoY), while the FY2025 annual figure was -$126.4 million, up 26.66% from the prior year.
• Free Cash Flow for Q4 2025 stood at -$54.4 million, up from -$58.3 million in the prior quarter.
• The five-year high for Free Cash Flow was $408.8 million in Q4 2021, with the low at -$109.7 million in Q3 2021.
• The 5-year median for Free Cash Flow is -$47.0 million (2021), against an average of -$25.3 million.
• Peak annual rise in Free Cash Flow reached 3523.67% in 2021, while the deepest fall reached 302.63% in 2021.
• Regenxbio's Free Cash Flow stood at $408.8 million in 2021, then tumbled by 109.15% to -$37.4 million in 2022, then advanced by 18.93% to -$30.3 million in 2023, then declined by 3.15% to -$31.3 million in 2024, then plunged by 73.96% to -$54.4 million in 2025.
• Business Quant data shows RGNX's Free Cash Flow at -$54.4 million in Q4 2025, -$58.3 million in Q3 2025, and -$46.2 million in Q2 2025.